Case

Redcliffe Labs

SDGS
https://impactfund.dk/wp-content/themes/impactfund/assets/dist/img/sdg-icons/good_health.svg https://impactfund.dk/wp-content/themes/impactfund/assets/dist/img/sdg-icons/reduce_inequality.svg
Facts
Year 2024
Sector Healthcare
Financial instrument Equity
Current investment DKK 137.8m
Regions Asia

Redcliffe Labs is a leading provider of diagnostic services in India, where kidney disease is widely spread. With the investment, Redcliffe Labs will be able to open 49 new pharmacies.

Theory of change: The establishment of new labs and expansions increase reliable and accessible diagnostic services, contributing to improved health and reduced premature mortality diseases.